Revance soars on exclusive distribution agreement with Teoxane

Revance Therapeutics

28/10/2024 10:59

** Anti-wrinkle injection maker Revance Therapeutics'  RVNC.O 
shares rise 20.6% to $5.67 premarket
** Company says it received exclusive distribution agreement to
import, sell and distribute in the U.S. a type of dermal fillers
made by Teoxane
    ** Says will also import and sell future Hyaluronic Acid
filler products made by Teoxane in the country
    ** Both dermal fillers and Hyaluronic Acid fillers are
injected under the skin to enhance its appearance
** In August, Revance agreed to be bought by privately held
Crown Laboratories in a deal valued at $924 mln
    ** As of last close, RVNC stock down 46.5% YTD

(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))